CytRx
Corporation (NASDAQ:CYTR), a biopharmaceutical research and
development company specializing in oncology, today announced that
President and CEO Steven A. Kriegsman and Vice President of Business
Development David Haen will present at the 16th Annual BIO
CEO & Investor Conference on Monday, February 10, 2014, at 2:30 p.m.
Eastern time (11:30 a.m. Pacific time). The conference is being held
February 10-11 at the Waldorf Astoria Hotel in New York City.
A live and archived webcast of the presentation will be available on the
Company’s website at www.cytrx.com/investors/presentations.
About CytRx Corporation
CytRx Corporation is a biopharmaceutical research and development
company specializing in oncology. CytRx currently is focused on the
clinical development of aldoxorubicin (formerly known as INNO-206), its
improved version of the widely used chemotherapeutic agent doxorubicin.
CytRx has completed a global Phase 2b clinical trial with aldoxorubicin
as a first-line therapy for soft tissue sarcomas, a Phase 1b/2 clinical
trial primarily in the same indication, a Phase 1b study of
aldoxorubicin in combination with doxorubicin in patients with advanced
solid tumors and a Phase 1b pharmacokinetics clinical trial in patients
with metastatic solid tumors. CytRx plans to initiate under a special
protocol assessment a pivotal Phase 3 global trial with aldoxorubicin as
a therapy for patients with soft tissue sarcomas whose tumors have
progressed following treatment with chemotherapy, and recently announced
that it has received approval from the FDA to continue dosing patients
with aldoxorubicin until disease progression in that clinical trial.
CytRx has initiated a Phase 2 clinical trial with aldoxorubicin in
patients with late-stage glioblastoma (brain cancer), and a Phase 2
clinical trial in HIV-related Kaposi’s sarcoma. CytRx plans to expand
its pipeline of oncology candidates based on a linker platform
technology that can be utilized with multiple chemotherapeutic agents
and may allow for greater concentration of drug at tumor sites. CytRx
also has rights to two additional drug candidates, tamibarotene and
bafetinib. CytRx completed its evaluation of bafetinib in the ENABLE
Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia
(B-CLL), and plans to seek a partner for further development of
bafetinib. For more information about CytRx Corporation, visit www.cytrx.com.
About the BIO CEO & Investor Conference
Now in its sixteenth year, the BIO CEO & Investor Conference is the
largest investor conference focused on established and emerging publicly
traded and select private biotech companies. Each year the BIO CEO &
Investor Conference provides a neutral forum where institutional
investors, industry analysts, and senior biotechnology executives have
the opportunity to shape the future investment landscape of the
biotechnology industry. The conference features issue-oriented plenary
sessions, educational sessions focused on hot therapeutic areas and key
business issues, company presentations, one-on-one meetings, and
networking opportunities.
Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of Section 21E of the Securities Exchange Act of 1934, as
amended. Such statements involve risks and uncertainties that could
cause actual events or results to differ materially from the events or
results described in the forward-looking statements. All forward-looking
statements are based upon information available to CytRx on the date the
statements are first published. CytRx undertakes no obligation to
publicly update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Copyright Business Wire 2014